Know Cancer

or
forgot password

Clinical Protocol for a Randomized Double-Blind, Placebo-Controlled Comparison of the Analgesic Activity of Valdecoxib (SC-65872) 40mg BID as Add-On Therapy to Opioid Medication in Patients With Chronic Cancer Pain


N/A
18 Years
N/A
Not Enrolling
Both
Pain, Unspecified Adult Solid Tumor, Protocol Specific

Thank you

Trial Information

Clinical Protocol for a Randomized Double-Blind, Placebo-Controlled Comparison of the Analgesic Activity of Valdecoxib (SC-65872) 40mg BID as Add-On Therapy to Opioid Medication in Patients With Chronic Cancer Pain


OBJECTIVES: I. Assess the analgesic efficacy of valdecoxib administered in addition to
opioid medication in patients with chronic pain due to cancer or prior cancer therapy. II.
Assess the safety of this drug in these patients.

OUTLINE: This is a randomized, double-blind, placebo-controlled study. Patients are
stratified according to baseline average pain intensity score (2-4 vs 5-11). Patients are
randomized to 1 of 2 treatment arms. Patients undergo a pretreatment period of 3-14 days to
determine daily dose of sustained release and immediate release opioid medications required
to adequately control pain with tolerable side effects. Arm I: Patients receive oral
valdecoxib twice daily in addition to opioid medications. Arm II: Patients receive oral
placebo twice daily in addition to opioid medications. Treatment continues for a maximum of
12 weeks in the absence of inadequate pain control or unacceptable toxicity. Patients record
daily pain assessments and total daily opioid consumption. Patients also are contacted by
telephone weekly for assessment of pain, opioid use, and adverse effects.

PROJECTED ACCRUAL: A maximum of 260 patients will be accrued for this study.

Inclusion Criteria


DISEASE CHARACTERISTICS: Chronic visceral or somatic pain due to cancer or prior cancer
therapy No pain primarily classified as neuropathic or unknown in nature Required opioid
analgesic at least 5 days/week for at least 2 weeks prior to study Expectation of
continued requirement for daily opioid medication (morphine sulfate, oxycodone, or
hydromorphone)

PATIENT CHARACTERISTICS: Age: Legal age and over Performance status: Karnofsky 60-100%
Life expectancy: At least 4 months Hematopoietic: Platelet count at least 40,000/mm3 No
platelet function disorder Hepatic: No known significant hepatic insufficiency Renal:
Creatinine less than 1.5 mg/dL BUN less than 1.5 times upper limit of normal Creatinine
clearance greater than 50 mL/min No known renal insufficiency Gastrointestinal: No
diagnosis of esophageal, gastric, pyloric channel, or duodenal ulceration within the past
30 days No history of esophageal or gastric cancer No intractable nausea or vomiting No
inability to swallow tablets or to tolerate oral medication Other: Weight at least 50 kg
No AIDS or AIDS-related cancers No history of hypersensitivity to cyclooxygenase
inhibitors (e.g., NSAIDs or specific COX-2 inhibitors) or opiates No significant alcohol,
analgesic, or narcotic substance abuse within the past 6 months No history of unstable
disease or condition that would preclude study Not pregnant or nursing Negative pregnancy
test Fertile patients must use effective contraception

PRIOR CONCURRENT THERAPY: Biologic therapy: Not specified Chemotherapy: At least 3 weeks
since initiation of new chemotherapy agent No concurrent participation in an
investigational chemotherapy trial Endocrine therapy: At least 2 weeks since initiation of
corticosteroids as an analgesic adjuvant Radiotherapy: At least 4 weeks since prior
radiopharmaceutical therapy or radiotherapy No concurrent radiopharmaceutical therapy or
radiotherapy Surgery: No concurrent therapeutic procedure (e.g., surgery or biopsy) that
would affect pain intensity Other: No prior participation on this study At least 30 days
since prior investigational agent At least 30 days since prior treatment for esophageal,
gastric, pyloric channel, or duodenal ulcer At least 8 weeks since initiation of
bisphosphonates At least 2 weeks since anticancer therapy that would affect study
evaluation At least 2 weeks since initiation of antidepressants, anti-epilepsy drugs, or
antihistamines as an analgesic adjuvant At least 5 half-lives since prior specific COX-2
inhibitors or non-steroidal anti-inflammatory drugs (NSAIDs) No concurrent other
investigational agent No concurrent anticancer therapy that would affect study evaluation
No concurrent other analgesics, specific COX-2 inhibitors, or NSAIDs except as
specifically permitted on study Concurrent acetaminophen less than 2 g/day allowed if
given 2 days or fewer per week Concurrent acetylsalicylic acid no greater than 325 mg/day
allowed

Type of Study:

Interventional

Study Design:

Primary Purpose: Supportive Care

Principal Investigator

Susana Campos, MD, MPH

Investigator Role:

Study Chair

Investigator Affiliation:

Dana-Farber Cancer Institute

Authority:

United States: Federal Government

Study ID:

CDR0000068670

NCT ID:

NCT00021996

Start Date:

January 2001

Completion Date:

Related Keywords:

  • Pain
  • Unspecified Adult Solid Tumor, Protocol Specific
  • unspecified adult solid tumor, protocol specific
  • pain

Name

Location

Dana-Farber Cancer InstituteBoston, Massachusetts  02115
Brigham and Women's HospitalBoston, Massachusetts  02115